Does the Form 4 state Raymond Anderson’s MNPR share holdings after these sales?

No. The non-derivative transaction rows do not report a total shares following transaction value, so his post-transaction Monopar Therapeutics share holdings are not stated in this Form 4 data.

Monopar director sells 3,142 shares in plan trade

Q: What insider activity did MNPR director Raymond Anderson report on this Form 4?

Raymond Anderson reported selling 3,142 shares of Monopar Therapeutics common stock on August 25, 2026 in three open-market transactions. All transactions were effected under a Rule 10b5-1 trading plan that he executed on May 26, 2026.

Q: At what prices were the MNPR shares sold in Raymond Anderson’s August 25, 2026 transactions?

The reported prices are weighted average prices per share: $110.04 for 694 shares, $110.07 for 646 shares, and $113.05 for 1,802 shares. Each weighted average reflects multiple trades within specified price ranges for that transaction.

Q: How many MNPR shares did Raymond Anderson sell in total on August 25, 2026?

He sold 3,142 shares of Monopar Therapeutics common stock in total, consisting of 694 shares, 646 shares, and 1,802 shares in three separate open-market sale transactions on August 25, 2026.

Monopar Therapeutics (MNPR) director Raymond Anderson reported selling a total of 3,142 shares of common stock on August 25, 2026 in three open-market transactions under a Rule 10b5-1 trading plan executed on May 26, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) director Raymond Anderson reported selling a total of 3,142 shares of common stock on August 25, 2026 in three open-market transactions under a Rule 10b5-1 trading plan executed on May 26, 2026. The reported per-share prices are weighted averages for shares sold across disclosed price ranges.

Insider Trade Summary 10b5-1

Net Seller: 3,142 shares

Net Sell 3 txns

Insider Anderson Raymond

Role Director

Sold 3,142 shs ($351K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	694	$110.04	$76K
Sale	Common Stock ^{F1, F3}	646	$110.07	$71K
Sale	Common Stock ^{F1, F4}	1,802	$113.05	$204K

Holdings After Transaction: Common Stock — 23,751 shares (Direct)

Footnotes (4)

F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

Key Figures

Shares sold (first transaction): 694 shares Weighted average price (first transaction): $110.04 per share Shares sold (second transaction): 646 shares +4 more

7 metrics

Shares sold (first transaction) 694 shares Common Stock sale on August 25, 2026 at a weighted average price

Weighted average price (first transaction) $110.04 per share Common Stock sale; prices ranged from $109.51 to $110.43

Shares sold (second transaction) 646 shares Common Stock sale on August 25, 2026 at a weighted average price

Weighted average price (second transaction) $110.07 per share Common Stock sale; prices ranged from $110.56 to $111.41

Shares sold (third transaction) 1,802 shares Common Stock sale on August 25, 2026 at a weighted average price

Weighted average price (third transaction) $113.05 per share Common Stock sale; prices ranged from $112.84 to $113.11

Total shares sold 3,142 shares Aggregate of three Common Stock sale transactions on August 25, 2026

Key Terms

Rule 10b5-1 Plan, weighted average price, multiple transactions

3 terms

Rule 10b5-1 Plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 Plan executed"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging from"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did MNPR director Raymond Anderson report on this Form 4?

Raymond Anderson reported selling 3,142 shares of Monopar Therapeutics common stock on August 25, 2026 in three open-market transactions. All transactions were effected under a Rule 10b5-1 trading plan that he executed on May 26, 2026.

At what prices were the MNPR shares sold in Raymond Anderson’s August 25, 2026 transactions?

The reported prices are weighted average prices per share: $110.04 for 694 shares, $110.07 for 646 shares, and $113.05 for 1,802 shares. Each weighted average reflects multiple trades within specified price ranges for that transaction.

Were Raymond Anderson’s MNPR stock sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 Plan executed by Raymond Anderson on May 26, 2026. The filing also checks the Rule 10b5-1 box, affirming plan-based trading.

How many MNPR shares did Raymond Anderson sell in total on August 25, 2026?

He sold 3,142 shares of Monopar Therapeutics common stock in total, consisting of 694 shares, 646 shares, and 1,802 shares in three separate open-market sale transactions on August 25, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/27/2026 - 06:28 PM EDT Accepted by SEC EDGAR 08/27/2026 - 06:27 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Raymond

(Last)

(First)

(Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE

ILLINOIS

60091

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/25/2026		S⁽¹⁾		694	D	$110.04⁽²⁾	26,169	D
Common Stock	08/25/2026		S⁽¹⁾		646	D	$110.07⁽³⁾	25,523	D
Common Stock	08/25/2026		S⁽¹⁾		1,802	D	$113.05⁽⁴⁾	23,751	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

	/s/ Quan Vu, Attorney-in-fact	08/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR